DOCSLIB.ORG

A Game-Changer Bridging the Gap Between Sustainability and Industry in the Field of Bio-Based Specialty Chemicals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Game-Changer Bridging the Gap Between Sustainability and Industry in the Field of Bio-Based Specialty Chemicals 7-8/2015 JULY INTERNATIINTERNATI NALNAL Chemicals Logistics How the cosmetics industry is THE NEWSPAPER FOR THE Recent developments and playing its part in current trends in sustainable development CHEMICAL AND supply-chain management Page 8 LIFE SCIENCE MARKETS Pages 9 – 12 © Africa Studio - Fotolia.com © Dmitry Perov - Fotolia.com A Game-Changer Bridging the Gap between Sustainability and Industry in the Field of Bio-based Specialty Chemicals ormed in 2007, Elevance Renewable Sciences produces high-performance As a high-performance, renewa- ingredients for use in personal care products, detergents, lubricants, and ble, collaboration-oriented company, we are in a unique market position Fother specialty chemicals and fuel markets from natural, plant-based oils. in the $500 billion specialty chemi- Based on its model, the Woodridge, Illinois, USA based enterprise claims to be the cal market. first company to successfully bridge the renewables and chemicals industries. What is your expectation for the Elevance is one of the companies that could revolutionize the specialty chemicals future market growth for bio- BUSS CHEMTECH value chain. CHEManager International asked Bob Kumpf, chief technology of- based specialty chemicals from EICKHOFF ficer at Elevance, about his strategy to further develop the company’s innovative natural oils? KRESTA KWE technologies and bringing novel bio-based specialty products onto the market. B. Kumpf: Future market growth will TRIPLAN be significant. Today, Elevance is VENTURIS IT commercially supplying partners CHEManager International: Where Using a proprietary and Nobel with better-performing, cost-com- Thank you for your visit has Elevance come from and how Prize-winning technology called petitive renewable alternatives to Bob Kumpf, CTO, to our stand at ACHEMA. did the company start? olefin metathesis, we have built and petrochemicals across multiple in- Elevance Renewable More information about now operate a 180,000 metric ton dustries. Through our groundbreak- Sciences our services on: www.kresta-industries.com B. Kumpf: Elevance began with a world-scale biorefinery in a joint ing technology, Elevance is deliver- grant from the US Department of venture with Wilmar International; ing and enabling high-performance Energy in 2004, and today we are a acquired and begun converting a specialty chemicals that meet criti- high-growth biochemistry company wholly owned biodiesel facility into a cal industry needs and trends. Our N EWSFLOW delivering specialty chemicals that second 310,000 metric ton biorefin- products, and those of our custom- exceed the performance of existing ery; established collaborations with ers, are helping the industry move M&A-News: products while leaving a smaller leading chemical industry players in beyond petrochemicals to something Celgene has agreed to pay $7.2 billi- on to acquire compatriot Receptos. environmental footprint. These feedstocks, technology, manufactur- that is better, a new generation of specialty chemicals are used in ing and markets; and commercial- chemistry with a smaller environ- Platform Specialty Products has personal care products, detergents ized a string of novel, high-perfor- mental footprint — a new category offered $2.3 billion for all shares and cleaners, engineered polymers, mance products that include clean- of products we call Renewicals. of UK-based Alent. lubricants and additives, and other ing and personal care ingredients More on Page 2 ▶ specialty chemicals markets. and a renewable synthetic base oil. Continues Page 7 ▶ Companies: Sanofi has announced plans to streamline its corporate structure Monsanto Steps up Pressure in Pursuit of Syngenta Inovyn Starts, BASF Quits PVC with effect from January 2016. gribusiness giant Monsanto in the near term” and also “a new ollowing clearance of the Ineos is planning to move some of its corporate functions back to is leaving no stone unturned company focused on accelerating merger by the European the UK. innovation and sustainability in in its quest to take over agriculture.” To legislators, he said Commission in mid-June, PVC More on Page 3 ▶ A F Swiss rival Syngenta. Since making an Monsanto intended to pay taxes producer Inovyn, the new 50:50 joint Investments: initial hostile $45 billion bid in May, its “on all US operations of the merged venture of Ineos and Solvay, officially BASF has commissioned a new company,” even if it moved corpo- production plant for form-release management has held meetings with rate headquarters to London, as has started trading on Jul. 1. agents at its Staßfurt, Germany, site. representatives of the Swiss company Michel Demaré, chairman of the board, Syngenta been suggested. Jean-Pierre Clamadieu, CEO, Solvay and its major shareholders as well as Behind the scenes in Europe, ob- Headquartered in London, the new Borealis plans to invest €160 million servers of the tussle are speculating company has pro forma sales of to upgrade and revamp four cracker US farmers and legislators. berg reported in mid-July that Paul- on which peripheral deals could be more than €3 billion, 4,300 em- PVC joint venture with Solvay for an furnaces at Stenungsund, Sweden. son & Co., the hedge fund of billion- forthcoming if, lured by the US of- ployees and assets across 18 sites undisclosed sum, effective Jul 1. As More on Page 9 and 14 ▶ Syngenta has continued to hold out, aire US investor John Paulson, had fer, Syngenta shareholders agree to in Belgium, France, Germany, Italy, part of the deal, Inovyn has agreed with supervisory board chairman acquired “a large number of shares” tender. Germany’s Bayer and BASF, Norway, Spain, Sweden and the UK. to supply basic chemicals to BASF’S People: Michel Demaré taking to YouTube to in Syngenta, which could place the both agricultural giants in their own The partners said final terms of Antwerp, Belgium, site. Evonik appointed Ralph Sven Kauf- mann as new COO, replacing Patrik present the company’s arguments. fund among the Swiss firm’s 20 larg- right, have been named as candi- the jv agreement remain “materially SolVin was established in 1999 Wohlhauser. In particular, he said the bid “gross- est shareholders. dates for Syngenta’s seed business, unchanged” from those announced a as a 75:25 joint venture of Solvay ly undervalues” the world’s largest Convincing US farmers that a which Monsanto undoubtedly would year ago, when plans were first re- and BASF. The German partner said More on Page 15 ▶ producer of chemical crop protect- deal between the two global be- have to sell to allay antitrust con- vealed. Upon closing, Solvay received at the time it intended to exit the ants and the US rival is downplaying hemoths will not further reduce cerns. an upfront cash payment of €150 mil- business at some point in the future. the execution risks inherent in such competition in the market for seed After a wave of mergers in recent lion from Ineos, subject to customary Unclear is whether SolVin will be a deal. “Monsanto has endorsed our and chemicals, and legislators that years, only six research-oriented adjustments such as actual working operated as a standalone company strategy and clearly demonstrated Monsanto will not move tax dollars agrochemical players are left in the capital levels. In addition to contrib- held by Inovyn or be absorbed by it. that it has great value,” Demaré outside the country have also been industry, and many have coopera- uting its entire European chlorovinyl Integration of the former Bel- said, but it is “trying to buy the com- at the top of the company’s to-do list tion pacts. “If the two biggest were business, Solvay has transferred li- gian-German jv is not known to pany “on the cheap.” this summer. to go together, inevitably it would abilities of around €260 million to have been included in the terms of Monsanto, which needs Syngenta In an “Open Letter to Growers” force others to review their strate- the new company. When the Belgian the EU approval of Inovyn but the to regain muscle in conventional published as a full-page advertise- gies,” Bayer CropScience chief Liam group sells its stake to Ineos in 2018, PVC producer would seem certain to crop protection after years of bet- ment in rural US newspapers, CEO Condon remarked in a news agency as agreed, it is due to receive an addi- be bound to through supply agree- ting mainly on seed, meanwhile ap- Hugh Grant said the combination interview. (dw) tional, performance-based payment ments. At the latest when Solvay ex- pears to have convinced at least one with Syngenta would “create a in the range of €95-280 million. its the business in 2018, full integra- major investor of the merits of its portfolio of choices that can im- Simultaneously, BASF announced tion into Ineos would appear likely. strategy. The news agency Bloom- prove your day-to-day-operations ▪ the sale of its 25% stake in its SolVin Commenting on the launch of Inovyn, Solvay CEO Jean-Pierre Clamadieu said the Belgian group’s transformation “has reached a key milestone.” Ineos chairman Jim Rat- cliffe said the joint venture “com- Load quickly bines two businesses with a strong · PF 11 05 64 · 69469 Weinheim · Pressepost · DPAG· Entgelt bezahlt · 78719 Entgelt · DPAG· · Pressepost Weinheim · PF 11 05 64 69469 heritage in the chlorovinyls industry, – safely creating a company fit to thrive in www.rs-seliger.de an ever changing business environ- WILEY VCH WILEY ment.” (dw) ▪ rs817gb-kleinanzeigen-2012-asvl-en-215x29-end.indd 1 23.03.2012 11:43:16 chemanager-online.com/en Page 2 MARKETS & COMPANIES CHEManager
Load more

Recommended publications
  • 2017 Annual Report on Form
    FORM 20-F 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Or ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value €2 per share New York Stock Exchange Ordinary shares, par value €2 per share New York Stock Exchange (for listing purposes only) Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2017 was: Ordinary shares: 1,254,019,904 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Annual Report on Form 20-F 2014
    FORM 20-F 2014 FORM 20-F 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) Ⅺ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ࠚ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or Ⅺ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or Ⅺ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boetie,´ 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boetie,´ 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one New York Stock Exchange ordinary share, par value e2 per share Ordinary shares, par value e2 per share New York Stock Exchange (for listing purposes only) Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2014 was: Ordinary shares: 1,319,367,445 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • PPCO Twist System
    Connect. Collaborate. Contribute. NOVEMBER 2016 Sanofi Genzyme: Expanding Beyond Rare Disease Into Specialty Care p. 18 David Meeker, executive VP and head, Sanofi Genzyme Clinical Trials 26 Allergan R&D 30 Biopharma 32 DC Insider 10 How A Chief Medical Officer Why The Company Women In Bio: Looking CEO Corner 12 Changed The Data-sharing Is Focusing On An Through The Glass Ceiling Culture At J&J And Across “Open-Science Platform” Companies To Watch 16 The Industry Global Update 48 Bringing together the best of When it’s YOUR compound, every step matters. www.pfizercentreone.com API DRUG PRODUCT PC1-16-0005-8.25x10.875 in-Mar., 2016 © 2016 Pfizer Inc. All rights reserved. inVentiv Health. Genetically engineered for success in the new pharmaceutical world. inVentiv Health processes and capabilities can accelerate business performance. The fact is, getting a new drug across the fi nish line is hard work every day. But lately, the challenges have increased exponentially. Today, it’s not enough to simply obtain regulatory approval; market success is now as mission-critical as trial success. Smart outsourcing partners begin with the end in mind. That’s why inVentiv purpose-built an organization in which both clinical and commercial work together under one roof as teammates and colleagues, not distant relatives. From early development through product launch, they share knowledge capital, data and insights. Our superior clinical trial design combined with highly effective commercial launch capabilities creates a unique environment in which processes and systems are constantly being challenged and evolved with an eye towards greater effi ciency, higher quality and, of course, getting to market faster.
    [Show full text]
  • Sanofi 1 4.5
    DOCUMENT DE RÉFÉRENCE 2017 SOMMAIRE 4 RESPONSABILITÉ SOCIALE, AVERTISSEMENT AU LECTEUR I ENVIRONNEMENTALE CHIFFRES CLÉS III ET SOCIÉTALE 355 ABRÉVIATIONS VI 4.1. Informations sociales 356 4.2. Informations santé, sécurité, environnement 371 4.3. Informations relatives aux 1 engagements sociétaux en faveur du développement durable 386 4.4. Plan de vigilance 400 PRÉSENTATION DE SANOFI 1 4.5. Note méthodologique sur le reporting des données 403 1.1. Principales informations relatives à 4.6. Rapport de l’organisme tiers la société 2 indépendant 407 1.2. Gouvernement d’entreprise 8 4.7. Tableau des indicateurs des entités juridiques france 410 2 5 ACTIVITÉ DE SANOFI 77 SANOFI ET SES ACTIONNAIRES 413 2.1. Historique et évolution de la société 79 5.1. Sanofi en bourse 414 2.2. Présentation de l’activité de Sanofi 79 5.2. L’information aux actionnaires 417 2.3. Organisation de l’entreprise 128 2.4. Investissements – principaux établissements 129 2.5. Litiges 133 6 2.6. Événements récents 136 PERSONNES RESPONSABLES, 3 ATTESTATION ET TABLES DE CONCORDANCE 421 6.1. Personne responsable RAPPORT DE GESTION, du document de référence 422 ÉTATS FINANCIERS ET 6.2. Attestation du responsable du document de référence INFORMATIONS FINANCIÈRES contenant un rapport financier COMPLÉMENTAIRES 137 annuel 422 3.1. Rapport de gestion relatif à 6.3. Personnes responsables l’exercice 2017 138 du contrôle des comptes 422 3.2. Rapport de la direction de Sanofi 6.4. Rapport des commissaires sur le contrôle interne relatif à aux comptes sur les prévisions l’information financière 203 de bénéfice net des activités par action 423 3.3.
    [Show full text]
  • Sanofi Fires Viehbacher After Fall out with Board
    OTC07-11-14p1_OTC15/11/2005 p1&24 05/11/2014 09:07 Page 1 7November 2014 COMPANY NEWS 3 Bayertakes leading spot 3 Sanofi fires Viehbacher in ChinawithDihon deal BoehringersaysnotoOmegabuy 3 GSKhints at Consumer divestments 4 afterfall out with board Merck waves goodbye to 5 Consumer Care business hris Viehbacher,chief executive officer Bayertargets critical mass 6 in Consumer Cof Sanofi, has been firedafter the firm’s board of directors concluded that his “man- Nasacortdrives salesforward 7 at Sanofi agement style was not adequate”. Oriola wantsafairprice 8 In asurprise move,the board of the French for itsRussian operations companyannounced it had “decided unani- BioGaiareports a 9 mously” to remove Viehbacher after six years double-digitsales rise at the helm. Celesioputsfaith in 11 “The group needs to pursue its development new leadership team with amanagement aligning the teams, harness- Pfizer expects Lipitortrialresults 12 ing talent and focusing on execution with aclose in 2015 and confident co-operation with the board,” Sanofistated, adding that its chairman, Serge GENERAL NEWS 13 Weinberg, would takecharge while it search- ed for achief executive. Most Germans have 13 Expanding on the rationale behind the deci- used homoeopathy sion, Weinbergsaid that the board was“strongly Chris Viehbacher has left Sanofi after the board Health Canada approves 16 dissatisfied” with Viehbacher’sability to work Aspirin heart-attack claim criticised his management style with board members to examine the company’s Germans reject OTCguidance 16 strategy “in aconfident manner”. (OTC bulletin,27February 2009, page 1). Australia settooverhaul 17 “The fluidity of the relationship between Acquisitions were central to Viehbacher’s TGAmedicines regulation the chief executive officer and the board was expansion strategy,with the companysnapping MARKETING NEWS 18 inadequate,”herevealed.
    [Show full text]
  • Annual Report on Form 20-F 2018
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value€2 per share NASDAQ Global Select Market Ordinary shares, par value€2 per share NASDAQ Global Select Market* Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2018 was: Ordinary shares: 1,245,454,385 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Sanofi R&D Chief Zerhouni
    Scrip Asks... IO Roundtable Expert View Do experts see orphan drug pricing Five companies talk about their place New products are set to shake the coming under pressure over the next in immuno-oncology (p10) hemophilia market – but convincing five years? (p4) payers will be a challenge (p14) 10 March 2017 No. 3844 Scripscrip.pharmamedtechbi.com Pharma intelligence | informa consultant to Sanofi; it gained steam when he joined Sanofi in his present position. “I structured the strategy for Sanofi in two phases. The first phase was how do we build a pipeline to be delivered in 2015, 2016, 2017 when we had loss of exclusiv- ity on key products, with Lantus being the last major drug after Plavix and others that lost their patents. The goal was how to do it without breaking the bank,” Zerhouni told Scrip in a recent interview. That initial revamp involved overhauling the pipeline and trimming 19 Phase II and Phase III programs from Sanofi’s R&D pipe- line between 2009 and 2012. Some of the programs missed Phase II endpoints. Oth- ers were discontinued because the value Elias Zerhouni proposition wasn’t there from either the patient or payer perspective. “I modified the strategy in a big way, by putting development first: we have to Sanofi R&D Chief Zerhouni: take care of development and underneath all that, start to fix research, not the other way around. Most heads of R&D, are heads How I’m Doing More With Less of R&D; I said, ‘No, I want to be a head of Elias Zerhouni says Sanofi’s ongoing R&D revamp has produced improved D&R,’ rather than R&D at Sanofi,” Zerhouni innovative results with controlled spending, in part by emphasizing cutting- explained.
    [Show full text]
  • FORM 20-F 2015 UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    FORM 20-F 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value €2 per share New York Stock Exchange Ordinary shares, par value €2 per share New York Stock Exchange (for listing purposes only) Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2015 was: Ordinary shares: 1,305,696,759 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Whale Watching: What a Decade of Change at Big Pharma Taught Us About Corporate Phenotypes by Endpoints Contributor on April 25Th, 2019
    Whale watching: What a decade of change at Big Pharma taught us about corporate phenotypes by Endpoints Contributor on April 25th, 2019 Contributed by Forbion Authored by Ivan Burkov1,2, Asiya Giniatullina1, Geert-Jan Mulder1, Sander van Deventer1,3,4 Affiliations: 1: Forbion; 2: Inkef Capital; 3: uniQure biopharma BV; 4: Leiden University Medical Center Confronted with decreasing R&D productivity and scarcity of true new blockbusters, pharmaceutical companies continuously seek growth opportunities by adopting new organizational structures and business strategies. These changes can be distinguished into global adaptive trends within the industry, such as the development of transformative therapies for rare diseases, and pharma-specific approaches, for instance the choice between relying on organic growth or increasing partnering and business development activities. Understanding the drivers behind strategic changes within the pharmaceutical industry is of significant interest to numerous stakeholders, including venture capitalists. Therefore, we have attempted to capture and explain recent key change events for several companies within the big pharma league. This “whale watching” exercise has revealed interesting insights regarding the industry and helped us to identify key behavioral patterns of big pharma companies. In our analysis, we have studied a representative sample of some of the largest multinational public pharma companies, looking at three key types of events that happened over the past decade: mergers and acquisitions (M&A), divestments, and key corporate development events (such as restructuring and strategy shifts). We have made use of the Global Data and publicly available resources to compile the dataset. Below we describe our findings and discuss their relevance in light of the ongoing evolution of the pharmaceutical and biotech industries.
    [Show full text]
  • Meet the New Lantus, Same As the Old Lantus
    February 26, 2015 Meet the new Lantus, same as the old Lantus Jonathan Gardner The good news for Sanofi is that the all-important extension of its insulin franchise, Toujeo, earned first-pass FDA approval. The bad news is that the regulator does not think it is much different from predecessor Lantus. Toujeo’s failure to achieve a claim of hypoglycaemia benefit makes it look rather undifferentiated at a time when the French group must cut prices to preserve Lantus market share and prepare for the launch of competitors. With just 16 months left in the patent life of its biggest seller, Sanofi’s board will be handing incoming chief executive Olivier Brandicourt a challenging dossier when he assumes control in April. Non-inferior, not superior Lantus, a once-daily insulin, is the best-selling drug in the diabetes space and third-biggest pharma product in the world. Although it has withstood a test in novel offerings from Novo Nordisk, first with Levemir and then with the Europe-only product Tresiba, its patent estate will evaporate in mid-2016 when a judicial stay lifts on the launch of Eli Lilly’s biosimilar, Basaglar (Lilly needs diabetes foundation to remain firm, January 31, 2014). To protect sales of its top franchise, Sanofi has developed Toujeo, a more concentrated depot formulation of Lantus’ active ingredient, insulin glargine, that has a slower and more sustained release. The objective was to achieve a flatter delivery curve to avoid insulin peaks that can lead to dangerous dips in blood sugar – most importantly, the nocturnal hypoglycaemia that can go unnoticed and result in greater complications.
    [Show full text]
  • Hudson to Succeed Brandicourt As Sanofi
    No. 3959 June 14, 2019 him all the assets he needs to accelerate growth and lead the group’s adaptation to new strategic challenges, particularly in the areas of R&D and digital.” He went on to say that the “human values” of Hudson, a Brit- ish citizen and avid supporter of Manches- ter United, will “enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world.” It was no secret that Brandicourt, who joined from Bayer AG in 2015, was look- ing to retire and Sanofi began the search for his successor earlier this year. Never- theless, observers were surprised that the search produced a candidate so quickly to replace the Frenchman, who Weinberg thanked “for the energy with which he has steered the group through a complex period and for his decisive contribution Hudson To Succeed Brandicourt to the company’s return to growth.” As Sanofi CEO TSCHUDIN NEW PHARMA HEAD FOR NOVARTIS KEVIN GROGAN [email protected] Hudson’s replacement will be Marie- France Tschudin, currently president of anofi’s search for a new CEO to re- Hudson has built up Advanced Accelerator Applications SA, place Olivier Brandicourt, who has the French nuclear medicine specialist Sdecided to retire, has ended with an impressive track that Novartis acquired last year, gaining the appointment of Paul Hudson, head of access to its approved peptide receptor ra- pharma at Novartis AG, to its top post.
    [Show full text]
  • Annual Report 2015 Contents
    ANNUAL REPORT 2015 CONTENTS VISION AND MISSION -------------------------------------------------------------------------------------------------- 2 GROUP HISTORY ------------------------------------------------------------------------------------------------------- 3 GROUP PROFILE -------------------------------------------------------------------------------------------------------- 4 STRATEGIC OBJECTIVES ---------------------------------------------------------------------------------------------- 5 OUR VALUES ------------------------------------------------------------------------------------------------------------ 6 SANOFI PAKISTAN CORPORATE PROFILE -------------------------------------------------------------------------- 7 NEW CEO OF SANOFI IN PAKISTAN ---------------------------------------------------------------------------------- 8 COMPANY INFORMATION --------------------------------------------------------------------------------------------- 9 DIRECTORS’ PROFILE -------------------------------------------------------------------------------------------------10 CORPORATE STRUCTURE -------------------------------------------------------------------------------------------12 MANAGEMENT COMMITTEE -----------------------------------------------------------------------------------------13 CORPORATE GOVERNANCE -----------------------------------------------------------------------------------------14 PRODUCTS -------------------------------------------------------------------------------------------------------------16 MEDICAL ----------------------------------------------------------------------------------------------------------------23
    [Show full text]